Brind.
  1. Capricor Therapeutics is seeking regulatory approval from the FDA for therapeutics targeting Duchenne Muscular Dystrophy.

The FDA is reviewing the Biologics License Application (BLA) submission from Capricor Therapeutics regarding its therapeutics for Duchenne Muscular Dystrophy (DMD).

4 reports, 2 independent Updated 02:15
Still developing
Reports
4
Developments
2
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

The FDA is reviewing the Biologics License Application (BLA) submission from Capricor Therapeutics regarding its therapeutics for Duchenne Muscular Dystrophy (DMD).

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. FDA issued a Complete Response Letter rejecting Capricor's Deramiocel BLA1 source
  2. FDA initiated review of Capricor's BLA submission for DMD therapeutics.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped